Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program
March 25, 2020 10:00 ET
|
Sorrento Therapeutics, Inc.
STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virusThe I-Cell vaccine is...